Amgen's Lumakras approved by the FDA

May 31, 2021
Amgen's Lumakras approved by the FDA

One of the world's leading biotechnology companies revealed that the Food and Drug Administration cleared its key lung cancer treatment

Amgen's Lumakras, a medicine designed to treat a non-small cell lung cancer with a specific mutation gene known as KRAS, was cleared by the FDA on Friday.

According to data from Amgen, Lumakras shrank tumours having the KRAS mutation in about 36% of patients in clinical trials. "The LUMAKRAS development program was a race against cancer for Amgen's scientists and clinical-trial investigators who together have now successfully delivered this new medicine to patients in less than three years -- from the first patient dosed to U.S. regulatory approval," stated the company's Executive Vice President of Research David Reese.

FDA's decision came after last month’s proposal that the once-daily treatment be compared with a lower daily dose of the drug. Amgen agreed, and the results are expected in late 2022.

In March, Amgen announced the purchase of Five Prime Therapeutics for $1.9 billion to expand its cancer-drug pipeline.

Lumakras will be listed at $17,900 per month in the U.S.

Following the news, Amgen closed the trading session 1.2% up at $238.23 per share.


This information prepared by is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.

Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of

Recently Added

Most Affected Instruments

amgen chart